For Immediate Release

      BrainStorm Cell Therapeutics Appoints Dr. Robert Shorr to the Board of
Directors Renowned Scientist, Entrepreneur and Business Development Veteran to
Add Significant Value in Creating Alliances, Financing and Development


Tel Aviv, Israel - March 31, 2005 - BrainStorm Cell Therapeutics (OTC BB:
BCLI.OB), an emerging company in stem cell therapeutics for neurodegenerative
diseases, today announced that Dr. Robert G.L. Shorr was appointed to the Board
of Directors.

Dr. Shorr has an eminent stature in the biotechnology and pharmaceutical space,
having participated in the financing, business growth and development of
multiple companies. His expertise varies from technological innovation through
strategic planning and implementation of research and business development, to
the founding, financing and guiding of full commercialization of biotechnology
ventures.

Currently, Dr. Shorr is President of Cornerstone Pharmaceuticals, engaged in
clinical development of a novel drug delivery technology for cancer .
Concurrently, as a member of the Department of Biomedical Engineering at SUNY
Stony Brook, he acts as Director of Business Development for the university's
Center for Advanced Technology. Since 1999 he has also served a trustee of
Tissue Engineering Charities, Imperial College, London. In addition, he has
continued financial interests and investments as a Principal in Altira Capital
and Consulting LLC

Prior to his current activities, Dr. Shorr was VP Science and Technology/Chief
Scientist for United Therapeutics/Unither (NASDAQ:UTHR) where he invented
PEGylated prostacylcin for pulmonary hypertension. From 1991 - 1998, as VP
Science and Technology at Enzon (NASDAQ:ENZN),he was responsible for the
development and regulatory approval of the blockbuster drug, PEG INTRON A, with
annual worldwide sales $1.5 billion for Hepatitis and Melanoma. Dr. Shorr's
track record also includes being Founder, VP Technology and Chief Scientific
Officer for AT Biochem, later sold to FMC and Associate Director, Department of
Molecular Pharmacology at SmithKline and French from 1982 - 1988.

Dr. Shorr has published more than 100 scientific/technical articles and has more
than 100 inventions, issued or patent-pending worldwide, many of them
commercialized. He holds a B.Sc. In Biology from the State University of
Buffalo, a D.I.C., from the University of London - Imperial College of Science
and Technology and a Ph.D. from the University of London.

"We are delighted and honored that Rob Shorr has joined our Board and believe
that his remarkable accomplishments will translate in to significant
contributions for the Company on all fronts to enable rapid progress towards
providing novel cell therapeutic solutions for treatment of debilitating and
incurable neurodegenerative diseases, such as Parkinson's disease," stated Dr.
Yaffa Beck, President and CEO.


About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like
stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow
derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM)
patent pending technology is based on discoveries made by the team of prominent
neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and
expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research
Center of Tel-Aviv University, enabling the differentiation of bone marrow
derived stem cells into functional neurons, as demonstrated in animal models.
The company holds rights to develop and commercialize the technology through an
exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd.,
the technology transfer company of Tel Aviv University. The company's initial
focus is on developing treatments for Parkinson's Disease.

About Stem Cell Therapy
Stem cells are non-specialized cells with a remarkable potential for both
self-renewal and differentiation into cell types with a specialized function,
such as muscle, blood or brain cells. Stem cells may be sourced from fetal or
embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of
embryonic stem cells, has become the center of significant ethical and moral
debate. In contrast, use of adult stem cells does not face the same moral or
legal controversy. Stem cell therapy aims to "cure" disease by replacing the
'diseased' cells with 'healthy' cells derived from stem cells. This approach has
the potential to revolutionize medicine and, if successful, the implied
commercial opportunities are great. Currently, both embryonic stem cells (ESC)
and adult stem cells (ASC) are being explored as the potential basis for
multiple cell therapy products.

About Parkinson's Disease
Parkinson's Disease (PD), which was first described by James Parkinson in 1817
as "the shaking palsy", is a chronic, progressive neurodegenerative disorder,
affecting the brain cells responsible for production of dopamine. The symptoms
include tremors, rigidity, slowness of movement and impaired balance. Over four
million people in the developed world, including as many as 1.5 million
Americans, mainly over the age of 65, are diagnosed with PD. That figure is
predicted to rise by 10% by 2010. Pharmaceutical treatments of PD with an
estimated combined annual market value of $4 billion, are insufficient to meet
patient needs. The search for more effective treatments continues.

Safe Harbor Statement:
Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc. actual results to differ
materially from those stated or implied by such forward-looking statements. The
potential risks and uncertainties include, among others, risks associated with
BrainStorm Cell Therapeutics Inc. limited operating history, history of losses
and expectation to incur losses for the foreseeable future; need to raise
additional capital to execute on its business plan; dependence on its license to
Ramot's technology and ability to meet its funding and payment obligations
included in such license agreement; ability, together with its licensor, to
adequately protect the NurOwn(TM) technology; dependence on key executives who
have recently joined the company and on its scientific consultants; ability to
identify, negotiate and successfully implement strategic partnering


relationships; ability to complete clinical trials successfully and to obtain
required regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining regulatory approval
for treatments in BrainStorm Cell Therapeutics Inc. market; the limited public
trading market for BrainStorm Cell Therapeutics Inc. stock which may never
develop into an active market; and other factors detailed in BrainStorm Cell
Therapeutics Inc. annual report on From 10-KSB, quarterly reports on Form
10-QSB, current reports on From 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to the
Company.